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SUMMARY
Histamine is involved in various physiological functions 
like sleep–wake cycle and stress regulation. The histamine 
N- methyltransferase (HNMT) enzyme is the only pathway 
for termination of histamine neurotransmission in the 
central nervous system. Experiments with HNMT knockout 
mice generated aggressive behaviours and dysregulation 
of sleep–wake cycles. Recently, seven members of two 
unrelated consanguineous families have been reported 
in whom two different missense HNMT mutations were 
identified. All showed severe intellectual disability, 
delayed speech development and mild regression from 
the age of 5 years without, however, any dysmorphisms or 
congenital abnormality. A diagnosis of mental retardation, 
autosomal recessive 51 was made. Here, we describe a 
severely mentally retarded adolescent male born from 
second cousins with a homozygous mutation in HNMT. 
His phenotypic profile comprised aggression, delayed 
speech, autism, sleep disturbances and gastro- intestinal 
problems. At early age, regression occurred. Treatment with 
hydroxyzine combined with a histamine- restricted diet 
resulted in significant general improvement.
BACKGROUND
Brain histamine, formed from the essential amino 
acid L- histidine, is a neurotransmitter and involved in 
several physiological functions like sleep–wake cycles, 
stress response and appetite. Two different enzymes 
are responsible for its inactivation, that is, diamine 
oxidase (DAO) and histamine N- methyltransferase 
(HNMT), located in chromosome 2q22.1 (OMIM: 
605238). DAO, also known as histaminase, is mainly 
expressed in the digestive tract and to a lesser extent 
in the kidneys and placenta, which indicates that 
this enzyme metabolises histamine in the peripheral 
organs but not in the central nervous system (CNS). 
In contrast, HNMT is widely expressed in the CNS, 
kidney and liver and catalyses the transfer of a methyl 
group from S- adenosyl- L- methionine to histamine, 
yielding N- methylhistamine and S- adenosyl- L- 
homocysteine (figure 1). Thus, inactivation of hista-
mine by HNMT is the only well- known pathway for 
the termination of neurotransmission action in the 
mammalian CNS.
As reported by several investigators, genetic single 
nucleotide polymorphisms of HNMT may play a 
role in a variety of human brain disorders such as 
Parkinson’s disease,1–3 and attention deficit disorder,4 
although that it is still not elucidated whether 
alterations in HNMT are primarily or secondarily 
involved.5 In addition, lowered histamine levels in 
cerebrospinal fluid have repeatedly been reported 
in patients with narcolepsy and other disorders with 
excessive daytime sleepiness.6 7 Finally, it is not clear 
whether polymorphisms of HNMT are also associ-
ated with gastrointestinal diseases.8
Animal experiments with HNMT knockout (KO) 
mice have demonstrated that HNMT deficiency 
enhances brain histamine concentrations indeed. As 
a consequence, the histamine KO mice showed high 
aggressive behaviours and experienced dysregulation 
of sleep–wake cycles.9 10
In recent years, a very limited number of patients 
have been described with a genetically caused defi-
ciency of HNMT. One patient, aged 23 years, with a 
deletion at 2q22.1q22.3 encompassing among others 
the HNMT gene showed a clinical picture charac-
terised by severe intellectual disability and several 
somatic anomalies related to other deleted genes.11 
Apart from this patient, two unrelated consanguin-
eous families of Turkish and Kurdish ancestry, respec-
tively, have been reported.12 The Turkish family with 
its background in Iraq had a total of nine children 
of whom four (two boys and two girls) showed 
profound to severe intellectual disability and speech 
was limited to single words. The condition was 
milder in the males as compared with the females 
and none of them had any neurological problems nor 
dysmorphisms, autism or congenital anomalies of any 
kind. All affected members showed mild regression 
from the age of 5 years. The Kurdish family with its 
origin in Iraq had seven children of whom three (two 
boys and one girl) presented with severe intellectual 
disability and delayed speech development. Similarly, 
these patients had no dysmorphisms or any congen-
ital malformations. Exome sequencing identified two 
different homogeneous missense HNMT mutations. 
In both families with affected members, ranged in 
age from 13 years to 35 years, a diagnosis of non- 
syndromic autosomal intellectual disability was estab-
lished that was named mental retardation, autosomal 
recessive 51 (MRT51; OMIM: 616739). These 
observations indicate that histamine modulates brain 
development and that HNMT plays an important 
role in human neurodevelopment.
Here, we describe in detail an adolescent male 
with severe intellectual disability from a family of 
second generation consanguinity in whom exome 




The patient is a 23- year- old severely intellectu-
ally disabled native Dutch man born from consan-
guineous parents in that the paternal grandmother 
of the patients’ father was a sister of the paternal 















2 Verhoeven WMA, et al. BMJ Case Rep 2020;13:e235972. doi:10.1136/bcr-2020-235972
Case report
grandmother of the patient’s mother. Father and mother are, 
therefore, second cousins. The patient was born after his mother 
had five miscarriages and one healthy son. Pregnancy and delivery 
were uncomplicated and during his first 2 years, development of 
speech, motor function and sociality were normal, although that 
he suffered from recurrent upper airway infections. Thereafter, 
however, global deterioration with loss of previously acquired 
capacities, especially language, became apparent and severe aggres-
sive behavioural problems occurred. Moreover, it was no longer 
possible to make normal contact. Aged 3, at a specialised outpa-
tient department for child and adolescent psychiatry, a diagnosis 
of autism spectrum disorder was made, at that time also called 
childhood disintegrative disorder. One year later, the patient was 
referred to a child neurology clinic for evaluation of his develop-
mental regression. Somatic and neurological examination disclosed 
no abnormalities nor were there any dysmorphisms. Laboratory 
tests of relevant haematological and chemical parameters as well as 
extensive investigations, including MRI scanning of the brain, were 
all normal and a diagnosis of autistic retardation was made. In 
subsequent years, genetic, neurological, metabolic, ophthalmolog-
ical and dermatological examinations were performed as well as a 
second MRI of the brain under general anaesthesia. Again, no aeti-
ological explanation could be found for his developmental delay 
and the diagnosis of autistic retardation was confirmed. Because of 
his aggressive behaviour with temper tantrums, he stayed during 
daytime at an activity centre of an institute for people with intel-
lectual disabilities where several short- lasting pharmacological 
interventions were tried that all had to be stopped because of 
increase of disinhibited and aggressive behaviours (promethazine, 
methylphenidate and phenobarbital) or motor side effects (risper-
idone). Apart from challenging behaviours, there were persistent 
sleep disturbances as well as intermittent urine incontinence and 
diarrhoea.
First neuropychiatric referral
At the age of 12, he was referred for specialised neuropsychiatric 
evaluation to the first author. Behavioural observation revealed 
clear ritualistic, stereotyped and autistic traits with mood insta-
bility necessitating structured individual guidance in all situa-
tions to avoid overestimation with subsequent challenging and 
aggressive behaviours. He could not read, write, calculate or 
tell the time. Somatic and neurological examination showed no 
abnormalities and there were no dysmorphisms. Weight, height 
and head circumference were in accordance with his biological 
age. Relevant haematological and biochemical parameters were 
all normal. The patient communicated with simple few word 
sentences, body language and pictorial signs. As assessed with the 
Vineland Adapative Behaviour Scale (VABS13) developmental age 
scores on the domains of communication, motor skills, socialisa-
tion and daily activities were 19 months, 42 months, 11 months 
and 24 months, respectively, corresponding with severe intellec-
tual disability. At that time, he was treated by his mother with 
homeopathic compounds of which one also contained a very low 
dose of promethazine. For behavioural control, two times per 
day 0.4 mg haloperidol was added. To elucidate the aetiology of 
his severe intellectual disability, single nucleotide polymorphism 
(SNP) array analysis was performed that showed no abnormalities. 
Subsequently, specialised neuropsychiatric assistance was no longer 
needed.
Intermediate period
Aged 14, the patient developed severe headache, vomiting, neck 
flexion, urine incontinence and unstable gait on which haloperidol 
was discontinued. Since these symptoms worsened, multiple brain 
imaging was performed that demonstrated a brain tumour in the 
fossa posterior . He subsequently underwent fossa posterior crani-
otomy and a benign right- sided cerebellar haemangioblastoma was 
successfully removed (see figure 2 for preoperative MRI image of 
the brain and CT scanning 2 years later). Neurofibromatosis type 
I and Von Hippel- Lindau syndrome were genetically excluded. 
Thereafter, the patient functioned on his premorbid level without 
any neurological symptoms and returned to his parent’s home and 
continued during daytime the structured activity programme at 
his former institute for people with intellectual disabilities. Severe 
sleeping problems, intermittent urine incontinence and diarrhoea 
were still present. To improve his sleeping pattern, the treating 
physician prescribed 2 mg zuclopenthixol. Since no significant 
changes in his behaviour repertoire could be expected, neuropsy-
chiatric consultation was not requested. However, at the age of 
19, trio- based exome sequencing demonstrated a homozygous 
pathogenic nonsense variant in the first exon of the HNMT gene 
(g.138722149C>T:NM_006895.2:c.88C>T(p.Gln30*)) leading 
to a premature stop codon, which was confirmed by Sanger 
sequencing. Both parents were shown to be heterozygous carrier 
of this variant. Figure 3 shows the Sanger sequencing electrophero-
grams of the index patient and his parents. These findings corre-
sponded with a diagnosis of MRT51. Because of this finding, he 
was referred again for specialised neuropsychiatric evaluation.
Figure 1 Enzymatic activity of histamine N- methyltransferase 
(HNMT). HNMT catalyses the transfer of a methyl group from S- 
adenosyl- L- methionine to histamine, yielding N- methylhistamine and 
S- adenosyl- L- homocysteine (figure provided by PKCJ).
Figure 2 (A) Aged 14 years. Preoperative T2- weighted- Fluid- 
Attenuated Inversion Recovery (FLAIR T2) MRI image of the 
brain showing right- sided cerebellar cystic tumour (cerebellar 
haemangioblastoma) with slight peritumoral oedema and a maximum 
cross- section of 56 mm, leading to compression of the fourth ventricle 
and slight displacement to the left (enhancing mural nodule and 
supratentorial obstructive hydrocephalus not visible). (B) Aged 16 years. 
CT scan image of the brain showing small residual cyst only with cross- 
section of 20 mm without any compression of the fourth ventricle.
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Second neuropychiatric referral
At examination, aged 19, a similar behavioural repertoire was 
present as during the first consultation, aged 12, in that he still 
displayed autistic, ritualistic and challenging behaviours with 
aggressive acts and self injuries. Active language was restricted to 
single words or short and simple sentences. Somatic and neurolog-
ical examination disclosed no abnormalities. Height (172 cm) and 
weight (70 kg) were in accordance with his current biological age. 
Relevant haematological (eg, white blood cell count and thrombo-
cytes) and biochemical parameters (eg, vitamin status, thyroid and 
liver parameters, glucose and lipid spectrum) were all normal still. 
Pharmacological treatment comprised two times per day 40 mg 
pipamperone, irregularly combined with 15 mg mirtazepine or 
7.5 mg midazolam to improve his sleep pattern. Also, two times 
per day 20 mg omeprazole was prescribed. Again, psychological 
assessment was performed. Social and emotional development 
as measured with the Dutch scale for emotional development in 
people with intellectual disability (ESSEON- R14) corresponded 
with a developmental age of 12 months and 18 months, respec-
tively. As assessed with the VABS, developmental age scores on 
the domains of communication, daily activities and socialisation 
were 23 months, 23 months and 15 months, respectively, being not 
significantly different from those as established previously. With 
the Dutch scale for social life skills (SRZ15), a developmental age 
of 2–3 years was established, corresponding with a cognitive level 
of 2–4 years, enhancing the risk of overestimation. He was then 
referred to a university outpatient department for child and adoles-
cent psychiatry where the diagnosis of autism was confirmed. 
Subsequently, he attended the outpatient department of clinical 
pharmacology for treatment advice.
TREATMENT
Because of the demonstrated homozygous mutation in the HNMT 
gene resulting in the complete absence of a functional HNMT, 
treatment with the antihistaminergic drug hydroxyzine in a daily 
dose of 25 mg and a histamine- restricted diet was prescribed. 
Since their efficacy was doubtful, it was advised to stop the use 
of psychotropics as mentioned before with the exception of 
omeprazole.
OUTCOME AND FOLLOW-UP
Until now, aged 23, treatment with 25 mg hydroxyzine in combi-
nation with a histamine- restricted diet resulted in normalisation of 
the patient’s sleep–wake cycle, significant reduction of aggression, 
improvement of speech and receptive language capacities, and 
complete continence for urine and faeces. The patient (figure 4) 
still lives at his parents’ home following, like in previous years, 
during daytime an activity programme at the same institute for 
people with intellectual disabilities.
DISCUSSION
Here, a 23- year- old severely intellectually disabled Dutch male 
patient born from second cousins is described in whom trio- based 
exome sequencing demonstrated a homozygous mutation in the 
HNMT gene matching a diagnosis of MRT51. Apart from one 
male patient with a homozygous mutation of the HNMT gene but 
without any phenotypic description (DECIPHER (324 002)), to 
the best of our knowledge, this is the first patient with this genetic 
syndrome after the publication of seven individuals from two 
unrelated families of Turkish and Kurdish descent, respectively.12 
Like in the affected members of these two families, also in our 
patient, global regression occurred around the age of 4 years, most 
pronounced regarding speech and language, in the absence of any 
dysmorphic features or congenital anomalies. Although not explic-
itly mentioned in the description of the patient histories of the two 
unrelated families from Turkish and Kurdish descent, it can be 
assumed that in all, like in our patient, a diagnosis of autism could 
have been made.
Unfortunately, in the publication of Heidari and coworkers, no 
information is given about either sleep pattern and intestinal prob-
lems or advised treatment regimen. In the here described patient, 
treatment with the antihistaminergic compound hydroxyzine in 
combination with a histamine- restricted diet resulted in normal-
isation of sleep pattern, complete continence, improvement of 
active speech and a significant reduction of aggressive challenging 
behaviours.
In conclusion, the behavioural phenotype of HNMT- associated 
MRT51 may comprise not only regression with loss of earlier 
achieved capacities around the middle of the first decade, but also 
autism, dysregulation of sleep–wake cycle and intestinal problems. 
The latter two may be effectively treated with the antihistaminergic 
compound hydroxyzine in combination with a histamine- restricted 
diet. Because of the attained marked and long- lasting improve-
ment of this patients’ general functioning, in retrospect, the earlier 
postulated regression hypothesis may have to be reconsidered.
Figure 3 Sanger sequencing electropherogram of the index patient, 
and his parents showing in the grey field the homozygous mutations of 
the index patient (C replaced by T).
Figure 4 Picture of the patient without any dysmorphic features: (A 
and B) aged 17 years and (C and D) aged 23 years.
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Patient’s perspective
We, the parents of the described patient, have seen a significant 
improvement in general functioning after the diagnosis was 
established and our son started the medication in combination 
with the histamine- restricted diet. He is now much calmer, sleeps 
well, shows no more aggression and has become completely 
potty- trained. It is also noticeable that he has pleasure again 
in his activities within the daily activity centre. Finally, we as 
well as his institutional supervisors can make with simple terms 
much better contact with him. We are very happy with all these 
positive developments.
Learning points
 ► Medical professionals should consider whole exome 
sequencing as the starting point for aetiological investigation.
 ► Brain histamine is crucial in physiological functions like sleep 
and stress regulation.
 ► Histamine N- methyltransferase deficiency is associated with 
aggressive behaviours and mental retardation, autosomal 
recessive 51.
 ► Antihistaminergic compounds that pass the blood–brain 
barrier such as hydroxyzine, combined with a histamine- 
restricted diet, normalise sleep pattern, reduce levels of 
challenging behaviour and ameliorate communication.
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